Doravirine 100 mg
| Product Overview |
| Generic Name | Doravirine 100 mg |
| Brand Name(s) | Pifeltro® |
| Form | 30 Film‑coated oral tablets |
| Strength | 100mg Tablets |
| Therapeutic Class | Non‑nucleoside reverse transcriptase inhibitor (NNRTI) |
| ATC Code | J05AG06 |
| Manufacturing & Regulatory |
| Manufacturer | Merck & Co (developer & manufacturer of Pifeltro) |
| Country | India/USA/EU |
| GMP Compliance | WHO-GMP |
| DMF/CEP | Type II |
| COFEPRIS | Pending |
| Free Sale Certificate | Yes |
| Logistics & Export |
| MOQ | 10 pks |
| Shelf Life | 24 Months |
| Storage | Store below 25 °C; protect from moisture/light |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
| Documentation |
| Certificate of Analysis (COA) | Provided per batch |
| SDS | Available from manufacturer |
| CTD Summary | Upon Request |
Description
Indications & Usage: Doravirine is an NNRTI indicated for the treatment of HIV‑1 infection in treatment-naïve adults and in regimen-switch patients with virologic suppression (<50 copies/mL). It’s administered once daily (100 mg) with or without food and typically used in combination with other ARVs. Doravirine avoids common NNRTI resistance mutations and has fewer drug–drug interactions.
Request for Quote
